2026-03-30 11:45Financial Performance - The company's operating revenue for 2025 reached ¥6,670,181,013.25, representing a 14.91% increase compared to ¥5,804,657,336.92 in 2024 [22]. - Net profit attributable to shareholders for 2025 was ¥1,132,569,775.63, up 19.35% from ¥948,950,036.00 in 2024 [22]. - The cash flow from operating activities for 2025 was ¥1,407,585,059.70, reflecting a 12.22% increase from ¥1,254,337,014.51 in 2024 [22]. - Basic earnings per share for 2025 were ¥3.16, a 17.47% increase from ¥2.69 in 2024 [22]. - The net profit after deducting non-recurring gains and losses for 2025 was ¥1,036,509,205.54, which is a 22.01% increase from ¥849,537,214.96 in 2024 [22]. - The company reported a quarterly revenue of ¥2,040,303,882.27 in Q4 2025, contributing to a total annual revenue growth [27]. - The company achieved total revenue of 6.67 billion yuan, a year-on-year increase of 14.91%, with a constant exchange rate growth of 16.78% [34]. - The net profit attributable to shareholders was 1.133 billion yuan, a year-on-year increase of 19.35%, while adjusted net profit was 1.253 billion yuan, up 56.09% [34]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 13 RMB per 10 shares to all shareholders, with no stock bonus [5]. - The total cash dividend amount, including other methods, is RMB 1,046.48 million, which accounts for 100% of the distributable profit of RMB 1,867.60 million [138]. - The cash dividend policy complies with the company's articles of association and shareholder resolutions, ensuring the protection of minority shareholders' rights [137]. - The cash dividend distribution was completed for both A-shares and H-shares within the stipulated time [136]. Revenue Sources and Business Segments - Revenue from large pharmaceutical companies was 2.916 billion yuan, a year-on-year increase of 8.36%, while revenue from small and medium-sized pharmaceutical companies was 3.755 billion yuan, up 20.57% [35]. - The small molecule CDMO business generated revenue of 4.735 billion yuan, a year-on-year increase of 3.59%, with a gross margin of 46.83% [36]. - Emerging business services achieved revenue of 1.929 billion yuan, a year-on-year increase of 57.30%, with overseas revenue exceeding 240% growth [37]. - The chemical macromolecule CDMO business reported revenue of 1.028 billion yuan, a year-on-year increase of 123.72%, with overseas orders accounting for 58.42% [38]. - The biopharmaceutical CDMO business generated revenue of 294 million yuan, a year-on-year increase of 95.76%, with overseas project revenue accounting for 39.55% [40]. - The formulation CDMO business achieved revenue of 284 million yuan, a year-on-year increase of 18.44%, with a total of 200 projects executed [42]. Operational Efficiency and Capacity Expansion - The company plans to increase its production capacity for macromolecule solid-phase synthesis to 69,000L by the end of 2026 to meet future order demands [39]. - Clinical research services revenue reached 282 million yuan, a year-on-year increase of 26.53%, with 216 new projects initiated, including a more than 50% increase in new II/III phase clinical research projects [44]. - The company is currently conducting 294 clinical research projects, with 122 projects in clinical phase II and beyond [44]. - The company achieved a 1000-fold increase in enzyme activity within 4 weeks through new enzyme product development, significantly enhancing R&D efficiency [46]. - The company has established a 500L GMP workshop, successfully delivering 3 IND projects, and has a fully operational fermentation facility covering approximately 17,000 square meters [46]. Research and Development - R&D investment for 2025 is projected at 593 million yuan, accounting for 8.89% of revenue, with a total of 577 authorized patents, including 205 in synthetic biology [48]. - The company has a total of 400 patents authorized both internationally and domestically, showcasing its strong research and development capabilities [110]. - The company is focusing on expanding its capabilities in ADC drug development, addressing key technical bottlenecks in the industry [73]. - The company is actively pursuing new product development and technological advancements to maintain competitive advantage in the biopharmaceutical industry [117]. Market Position and Strategy - The company is a leading global pharmaceutical outsourcing service provider, focusing on drug research and development, and offers one-stop services for large and medium-sized pharmaceutical and biotechnology companies [4]. - The global CDMO market is expected to reach 124.3 billion USD by 2025, with a compound annual growth rate of 13.2% [51]. - The company has formed strong partnerships with major pharmaceutical companies, increasing the penetration rate of global pipelines [53]. - The company is recognized as a leading technology-driven CDMO, providing comprehensive solutions across the drug development and production process [54]. Governance and Compliance - The company has established a clear and independent governance structure, ensuring that the board of directors and management operate independently from the controlling shareholder [99]. - The board of directors consists of three independent directors, meeting the requirement of one-third of the total board members [100]. - The company has implemented a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal regulations [103]. - The company has established a dedicated investor relations management office to oversee communication and engagement with investors [101]. Employee and Management Structure - The company employed 10,617 staff, with 78.2% holding a bachelor's degree or higher, and 38.8% of R&D personnel being senior researchers [49]. - The total number of shares held by Zhang Da, the Chief Operating Officer and CFO, increased from 326,000 to 391,000 shares due to stock incentives [107]. - The company has a total of 342 employees with doctoral degrees and 2,193 with master's degrees [132]. - The company has established a dual career development path for management and technical positions, enhancing employee training and development [135]. Risk Management - The company faces risks including operational failures in clinical stage projects, lower-than-expected sales of innovative drugs, and potential impacts from international trade uncertainties and currency fluctuations [4]. - The company has established a derivative investment management system to control risks associated with derivative trading [85]. - The company has not reported any significant internal control deficiencies during the reporting period [150]. Community Engagement and Social Responsibility - The company has a long-standing commitment to social responsibility, focusing on quality products and services while pursuing sustainable development [155]. - The company actively participates in community support and social welfare initiatives, including funding for children with congenital heart disease [156]. - The company has contributed to rural revitalization efforts, including donations for infrastructure improvements in targeted villages [159].